Prostate Cancer Biomarker Panel for Accurate Blood-Based Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for prostate cancer, such as PSA testing, have low sensitivity and specificity, leading to either unnecessary biopsies or underdiagnosis, and there is a lack of molecular-based biomarkers for accurately diagnosing and monitoring prostate cancer progression and therapy response.
Innovation Solution
A method involving the detection of the expression levels of 38 biomarkers, including AAMP, AR-V7, and a housekeeping gene, followed by normalization and input into an algorithm to generate a score for diagnosing prostate cancer, determining its grade, stability, and monitoring therapy response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If PSA testing is used for prostate cancer detection, then the screening process is simple and widely available, but the sensitivity and specificity are low leading to unnecessary biopsies or underdiagnosis
Solution Approach 1:
The patent combines multiple biomarker assessments (including PSA and additional molecular markers) into a single integrated diagnostic system. This merging of multiple detection approaches allows the system to maintain the simplicity of blood-based screening while achieving higher diagnostic accuracy through the combined information from various biomarkers.
Solution Approach 2:
The diagnostic system uses a composite biomarker profile consisting of multiple molecular markers rather than relying on a single PSA measurement. This composite approach integrates different types of biological information (protein levels, gene expression, molecular signatures) to create a more accurate diagnostic tool that maintains ease of use.
2Measurement precision
If molecular-based biomarkers are developed for accurate prostate cancer diagnosis, then the sensitivity and specificity improve, but the complexity of the diagnostic method increases
Solution Approach 1:
The patent replaces complex invasive procedures (such as repeated biopsies and detailed pathological examinations) with a molecular-based blood test system. This substitution uses molecular signatures and biomarker profiles detected through biochemical assays, achieving high diagnostic accuracy without requiring complex mechanical or surgical interventions.
Solution Approach 2:
The patent introduces molecular biomarkers as intermediary indicators that mediate between the cancerous tissue and the diagnostic measurement. These biomarkers serve as surrogate markers that can be detected in blood samples, providing accurate information about tumor presence and characteristics without requiring direct examination of the tissue.
3Ease of operation
If current risk stratification systems are used, then the diagnostic process is straightforward, but the accuracy for predicting outcome is only about 70%
Solution Approach 1:
The patent changes the parameters used for risk stratification from traditional clinical and pathological factors alone to include molecular-based biomarker profiles. By incorporating molecular signatures, gene expression patterns, and specific biomarker levels, the system transforms the diagnostic parameters to achieve higher prediction accuracy while maintaining a systematic approach to patient stratification.
Data Source
AI summary
The present invention is directed to methods for detecting a prostate cancer, methods for determining whether a prostate cancer is stable or progressive, low or high Gleason score, methods for differentiating benign prostate hyperplasia (BPH) from prostate cancer, methods for determining the completeness of surgery, and methods for evaluating the response to a prostate cancer therapy.